Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Sarepta Therapeutics is down 49.2% since the beginning of the year, and at $62.99 per share, it is trading 61.6% below its 52-week high of $163.85 from June 2024.

Last month saw a slew of changes at the top of Western New York companies in fields ranging from health care to manufacturing to higher education. Read on to see who and where. April’s C-suite ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously approved ...

Fifth Third Bancorp has made some changes to its C-suite as one of its leaders retires. Bank’s Cincinnati-developed app wins prized J.D. Power award Fifth Third plans to expand its crypto ...

Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets for Immunovant's leading drug. Immunovant stock toppled 4 ...

Nashville-based health care staffing company Shearwater Health announced several C-suite changes in a Tuesday press release. Shearwater has named Matthew Thompson to the role of general counsel ...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS), Sarepta (SRPT), or PetCo (WOOF) To Contact Him Directly To Discuss ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2025 that were previ ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in ...